Market Capitalization (Millions $) |
3,468 |
Shares
Outstanding (Millions) |
338 |
Employees |
365 |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-88 |
Cash Flow (TTM) (Millions $) |
-54 |
Capital Exp. (TTM) (Millions $) |
7 |
Gracell Biotechnologies Inc
Gracell Biotechnologies Inc. is a clinical-stage biotechnology company focused on developing cell therapies for various types of cancers. The company was founded in 2017 and is headquartered in Suzhou, China, with additional facilities in the United States.
Gracell's approach to cancer treatment involves using a patient's own immune cells to fight the disease. They do this by taking T-cells, a type of white blood cell, from the patient and genetically modifying them using a proprietary platform known as FasTCAR. This process enables the T-cells to recognize and attack cancer cells more effectively while avoiding harm to healthy cells.
The company's flagship product, GC007g, is a potentially curative therapy for relapsed or refractory B-cell malignancies, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The treatment involves a single infusion of the modified T-cells, which have demonstrated high response rates and extended remission periods in clinical trials. Gracell is also developing a pipeline of additional cell therapies for various solid tumors and other blood cancers.
Gracell has established partnerships with several leading cancer research institutions and biopharmaceutical companies worldwide. These partnerships leverage Gracell's expertise in cell therapy development and their proprietary technology to advance the field of cancer treatment.
In addition to their scientific research, Gracell is committed to making their therapies accessible to patients worldwide. The company has established a global supply chain network to ensure their products can be manufactured and distributed efficiently and cost-effectively, while maintaining the highest standards of quality and safety.
Overall, Gracell Biotechnologies Inc. is a cutting-edge biotech company with a significant focus on innovation in cancer treatment. With a robust pipeline of potentially revolutionary cell therapies and a commitment to patient accessibility, Gracell is well-positioned to continue making significant advances in the fight against cancer in the coming years.
Company Address: Building 12, Block B, Phase II Suzhou 215123
Company Phone Number: 6262-6701 Stock Exchange / Ticker: NASDAQ GRCL
GRCL is expected to report next financial results on April 24, 2024. |
|
|